欢迎访问行业研究报告数据库

报告分类

重点报告推荐

当前位置:首页 > 行业导航

找到报告 18524 篇 当前为第 1 页 共 1853

检索词:

  • 1.中国农业问题报告与分析-第570期

    [农、林、牧、渔业,] [2020-09-28]

    农业农村部 9 月 7 日表示,《全国农药产业发展规划(2021 —2025 年)》,目前已形成初稿,分析了当前农药产业发展基础、面临的形势要求和问题挑战,提出了“十四五”发展的总体思路、目标任务、工作重点和保障措施。

    关键词:中国农业;土地改革;农药发展规划;土地要素改革;土壤修复;农牧物流;种猪品种
  • 2.全球黄斑变性治疗市场-增长,趋势和预测(2020-2025年)

    [医药制造业,] [2020-09-28]

    The macular degeneration treatment market is largely driven by rise in the incidence of retinal disorders and growing geriatric population across the world. The aging population is more likely to witness par tial loss of vision, abnormality where straight lines appear wavy, blurred vision, distorted vision, inability to witness in dim light, or spots and other macular degeneration disorders associated with pain. Between 25% and 50% of the community-dwelling elderly have been witnessing several retinal problems since the past few years. According to the data published in the European Society of Retina Specialists (EURETINA), currently, in Europe, an estimated number of 33.6 million persons over the age of 60 years are suffering from AMD. The increasing number of individuals suffering from retinal disorders is directly proportional to the market’s growth. This high prevalence rate denotes the importance of AMD treatment, primarily for treating the target disease. Furthermore, the increasing R&D investments and rising approvals for new drugs of the treatment are other major factors driving the market’s growth. Furthermore, numerous pharmaceutical manufacturers associated with the AMD market, particularly in emerging markets, such India, Brazil, and other nations witnessed significant growth and capitalized over the past decade.

    关键词:黄斑变性治疗市场;人口老龄化;视网膜疾病;治疗新药
  • 3.全球高内涵放映市场-增长,趋势和预测(2020-2025年)

    [仪器仪表制造业,医药制造业,计算机、通信和其他电子设备制造业,] [2020-09-27]

    The high content screening market is driven by factors, such as an increase in investments by the government and other organizations , technological advancements, and the expanding application areas. According to the Office for National Statistics (ONS), the total expenditure in R&D in the United Kingdom is increasing rapidly. During 2016, the expenditure was GBP 33.2 billion, which increased in 2017 and reached GBP 34.8 billion. Similarly, in the United States, the investment on medical R&D was USD 39.5 billion, in 2017. This indicates that a substantial investments were made in healthcare in the major countries. As the government and other organizations are investing more in research and development, the high content screening market is expected to register significant growth. The increase in R&D activities in Asia, particularly India. The consecutive annual growth in the expenditure in R&D in the country indicates a period of stability, security, and healthy competition across the industrial sectors. The high cost of the advanced technologies is expected to hinder the growth of the market. However, the increasing demand for advanced tools for drug developments, other studies, recent product launches are expected to boost the growth of the high content screening market.

    关键词:高内容放映市场;药物开发;高含量筛选市场
  • 4.医药行业:中报业绩企稳,关注长期投资逻辑-2020年4季度投资策略报告

    [医药制造业,] [2020-09-26]

    年初至今(2020 年1 月1 日至2020 年9 月10 日),申万医药生物板块上涨43.01%,沪深300 指数上涨11.85%,医药生物板块整体跑赢沪深300 指数31.16 个百分点,涨跌幅在申万28 个一级行业中排名第3 位,医药6 个子板块均以上涨报收;细分来看,具有科技属性的医疗器械和生物制品子板块表现抢眼,分别上涨了71.18%和68.97%;医药板块整体TTM 市盈率剔除负值后为47.15 倍,沪深300 市盈率为13.87 倍,医药板块相对沪深300 的估值溢价率为240%,处于2013 年来的高位水平。


    关键词:医药行业;中报业绩;投资策略
  • 5.医药生物行业:8月多数品种出现不同程度下滑-2020年1-8月血制品批签发

    [医药制造业,] [2020-09-26]

    2020年1-8月多数品种实现批签发量稳健增长。新兴事件过后,监管趋严,同时今年疫情导致上半年采浆减少,下半年供给有望趋紧,中长期来看,集中度有望提升,整体未来发展值得看好。8月多数品种批签发量有所下滑。 重点推荐华兰生物、双林生物、卫光生物、天坛生物等,建议关注博雅生物。


    关键词:医药生物行业;血制品;批签发
  • 6.医药生物行业:2020年08月疫苗行业批签发数据跟踪

    [医药制造业,] [2020-09-26]

    流感疫苗进一步放量,本月合计批签发907.77万支,同比增长68.48%,Sanofi进口流感疫苗再获批签发以弥补缺口。Sanofi三价流感疫苗重新批签发393.88万支;金迪克四价流感疫苗获今年首批,累计批签发59.59万;华兰生物四价放量并新增三价批签发,本月批签发四价流感疫苗158.23万,三价流感疫苗69.95万;北京科兴进一步放量,本月批签发三价流感疫苗104.63万;长春所批签发四价流感疫苗19.27万,三价流感疫苗56.39万。


    关键词:医药生物行业;疫苗行业;批签发
  • 7.医药生物行业:非小细胞肺癌靶向药EGFR-TKI前景广阔

    [医药制造业,] [2020-09-26]

    在过去5 年中,我国新发癌症病例增长率超过了全球和美国同期水平,2018 年中国新发癌症患者人数达到了428.5 万人,2014-2018 年CAGR为2.8%,预计2023 年中国将会有486.5 万名新发病患患者。2018 年肺癌为我国发病人数和发病率最高的癌种,分别为86.8 万人(接近第二名胃癌的2 倍)和0.062%,发病人数占比全球的41.4%。


    关键词:医药生物行业;靶向药;TK
  • 8.医药生物行业:国产化学发光乘风破浪-体外诊断行业系列报告

    [医药制造业,] [2020-09-26]

    国内化学发光免疫分析的投资价值判断,关键在于判断当前行业阶段和投资逻辑,对长期竞争格局演变的预判,最后落实到如何选择投资标的。本篇化学发光行业报告将从以下几点尝试回答这个问题。


    关键词:医药生物行业;国产化学;体外诊断
  • 9.医药生物行业:谱写新药诗篇的序章-浅析药物临床前研究过程

    [医药制造业,] [2020-09-26]

    近几十年来,随着药物作用靶点不断涌现、药物筛选和优化技术不断创新,全球小分子和大分子药物市场均保持着稳定较快的成长。同时,新药研发成本持续提升逐步成为行业常态,新药研发难度持续加大、新药研发成功率不断降低。


    关键词:医药生物行业;新药;研究过程
  • 10.医药生物行业:收入端受疫情影响增速暂放缓,利润端多个子板块高景气-中报总结

    [医药制造业,] [2020-09-26]

    医药上市公司中报均公布,我们选取了242 家医药上市公司,包括多个医药子领域,如原料药(不含维生素)25 家、化学制剂54 家、中药60 家、生物制药(不含血制品)16 家、血制品6 家、CXO9 家,医疗器械(不含高值耗材和IVD)23 家、高值耗材8 家、IVD16 家,医药流通企业16 家,零售5家。选取营业收入、扣非净利润、各项费用和毛利进行分析,对上市公司中报和年报相关指标进行加总,然后计算收入利润同比增速和费用毛利率。如果某期未披露,则前一年同期和后一年同期数据也不在计入加总,避免口径发生变化。

    关键词:医药生物行业;收入端;疫情
首页  上一页  1  2  3  4  5  6  7  8  9  10  ...  下一页  尾页  
© 2016 武汉世讯达文化传播有限责任公司 版权所有 技术支持:武汉中网维优
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服